tbuckley/cabot-search huggingface dataset:
Years of Potential Life Lost from Unintentional Injuries Among Persons Aged 0-19 Years—United States, 2000-2009
Journal: JAMA (2013)

Unintentional injuries are the leading cause of deaths among persons aged 0-19 years in the United States. Quantifying years of potential life lost (YPLL) highlights childhood causes of mortality and provides a simple method to identify important causes of premature death and specific groups in need of intervention. Deaths attributed to unintentional injuries among persons aged 0-19 years number approximately 12,000 each year in the United States; another 9 million young persons are treated for nonfatal injuries in emergency departments. To estimate the burden of premature deaths attributed to unintentional injuries among persons aged 0-19 years, CDC calculated state-specific YPLL by sex, age, race, and injury mechanism based on data from the National Vital Statistics System multiple cause of death files for the period 2000-2009. This report summarizes the results of that analysis, which found that an average of 890 years of potential life were lost each year because of unintentional injuries for every 100,000 persons aged 0-19 years. The burden of unintentional injuries was higher among males compared with females, among persons aged <1 year and those aged 15-19 years compared with the other 5-year age groups, among American Indian/Alaska Native (AI/AN) compared with those of any other race/ethnicity, and among those residing in two clusters of adjacent states (the South Central states of Arkansas, Louisiana, Mississippi, and Alabama, and the Mountain states of Montana, Wyoming, and South Dakota) compared with any other region. These estimates can be used to target injury prevention strategies to young persons most at risk.
BOOK REVIEWS
Authors: MARY S. MCCABE
Journal: JNCI Journal of the National Cancer Institute (1992)

BOOK REVIEWS Get access Effect of Cancer on Quality of Life David Osoba , ed. Boca Raton, Fla. : CRC Press , 1991 . 353 pp., illus. $89.95. ISBN 0-8493-6977-0 MARY S. MCCABE MARY S. MCCABE Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 84, Issue 24, 16 December 1992, Page 1932, https://doi.org/10.1093/jnci/84.24.1932 Published: 16 December 1992
Anti-HIV Drugs Continue To Fight HIV Infection after 3 Years
Journal: Annals of Internal Medicine (2000)

Summaries for Patients4 July 2000Anti-HIV Drugs Continue To Fight HIV Infection after 3 YearsSearch for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-133-1-200007040-00027 SectionsAboutFull Text ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail What is the problem and what is known about it so far?Anti-HIV medication regimens that include the powerful drugs called protease inhibitors decrease the amount of HIV in the blood of patients with HIV infection. Decreases in the amount of the virus in the blood are associated with better clinical outcomes for patients. However, it is still not known how long these multiple-drug medication regimens remain effective.Why did the researchers do this particular study?The researchers wanted to find out whether a three-drug medication regimen to treat HIV infection continues to keep the amount of virus in the ... Author, Article, and Disclosure InformationAffiliations: The summary below is from the full report titled “3-Year Suppression of HIV Viremia with Indinavir, Zidovudine, and Lamivudine.” It is in the 4 July 2000 issue of Annals of Internal Medicine (volume 133, pages 35-39). The authors are R.M. Gulick, J.W. Mellors, D. Havlir, J.J. Eron, A. Meibohm, J.H. Condra, F.T. Valentine, D. McMahon, C. Gonzalez, L. Jonas, E.A. Emini, J.A. Chodakewitz, R. Isaacs, and D.D. Richman.Summaries for Patients are a service provided by Annals to help patients better understand the complicated and often mystifying language of modern medicine.Summaries for Patients are presented for informational purposes only. These summaries are not a substitute for advice from your own medical provider. If you have questions about this material, or need medical advice about your own health or situation, please contact your physician. The summaries may be reproduced for not-for-profit educational purposes only. Any other uses must be approved by the American College of Physicians-American Society of Internal Medicine. Previousarticle Advertisement FiguresReferencesRelatedDetailsSee Also3-Year Suppression of HIV Viremia with Indinavir, Zidovudine, and Lamivudine Roy M. Gulick , John W. Mellors , Diane Havlir , Joseph J. Eron , Anne Meibohm , Jon H. Condra , Fred T. Valentine , Deborah McMahon , Charles Gonzalez , Leslie Jonas , Emilio A. Emini , Jeffrey A. Chodakewitz , Robin Isaacs , and Douglas D. Richman Metrics 4 July 2000Volume 133, Issue 1Page: 35KeywordsAdverse reactionsBloodBlood cellsCellsDrug therapyDrugsHIV infectionsHematologic testsViral loadViremia ePublished: 15 August 2000 Issue Published: 4 July 2000 Copyright & PermissionsCopyright © 2000 by American College of Physicians. All Rights Reserved.Loading ...
VENEREAL DISEASES AND THE PUBLIC HEALTH.
Journal: JAMA (2006)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Axitinib versus sorafenib as second‑line therapy in Asian patients with metastatic renal cell carcinoma (mRCC): Results from a registrational study.
Authors: Shukui Qin, Feng Bi, Ying Cheng, Jun Guo, Xiu Bao Ren, Yiran Huang, Jinwan Wang, Yong Ben, Sinil Kim, Jie Tang, Dingwei Ye
Journal: Journal of Clinical Oncology (2012)

LBA4537 Notice of Retraction: "Axitinib versus sorafenib as second-line therapy in Asian patients with metastatic renal cell carcinoma (mRCC): Results from a registrational study." Abstract LBA4537, published in the 2012 Annual Meeting Proceedings Part II, a supplement to the Journal of Clinical Oncology, has been retracted by Shukui Qin, MD, on behalf of all authors of the abstract. The adjudication portion of the Independent Review Committee (IRC) tumor assessments were incomplete for some of the ongoing patients in the study reported in the abstract and the adjudication could not be completed in time for presentation at the 2012 ASCO Annual Meeting. Background: An earlier phase III trial in 723 patients with previously treated mRCC demonstrated significantly longer progression-free survival (PFS) for axitinib, a potent and selective second-generation inhibitor of vascular endothelial growth factor receptors, compared with sorafenib. We conducted a multicenter, randomized, open-label trial to estimate PFS for axitinib and sorafenib in 204 Asian patients with previously treated mRCC. Methods: Patients with an Eastern Cooperative Oncology Group performance status (ECOG PS) 0 or 1 and measurable, clear-cell, mRCC that had progressed after 1 prior first-line systemic regimen (sunitinib or cytokines) were randomly assigned (2:1) to 28-day cycles of axitinib 5 mg twice daily (BID) or sorafenib 400 mg BID. Axitinib dose reductions and stepwise dose titrations to 7 mg BID and then 10 mg BID, as tolerated, were allowed; sorafenib dose reductions to 400 mg daily or every other day were also allowed. Primary endpoint was PFS per independent review committee. Results: Patients were stratified by ECOG PS and prior first-line systemic therapy: 135 received axitinib and 69 received sorafenib.Baseline patient characteristics included median age 56 years, 70% male, 99% Asian, and 63% ECOG PS 0. Prior therapy included sunitinib (45%) or cytokines (53%). Median PFS was 6.4 months (95% confidence interval: 4.6, 8.3) with axitinib and 4.8 months (2.8, 6.5) with sorafenib. Objective response rates were 23.7% with axitinib and 10.1% with sorafenib. All-grade adverse events in ≥15% of patients (axitinib, sorafenib) included hypertension (50%, 36%), weight decreased (37%, 33%), diarrhea (34%, 30%), hand-foot syndrome (32%, 57%), decreased appetite (30%, 20%), hypothyroidism (28%, 23%), fatigue (27%, 23%), proteinuria (21%, 20%), dysphonia (19%, 9%), cough (16%, 16%), rash (15%, 28%), pyrexia (7%, 16%), alopecia (3%, 22%). Conclusions: Asian patients receiving axitinib as second-line therapy for mRCC had a similar PFS and objective response rate as in a previous global phase III trial, with an acceptable safety profile.
Diagnostic and therapeutic technology assessment. Continuous peritoneal insulin infusion and implantable insulin infusion pumps for diabetic control
Journal: JAMA (1989)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
National Association of General Practitioners
Journal: BMJ (1846)

In the article in our last Number, in which we examined, at such length, the new Medical Bill in all its bearings, we stated, after much consideration, " that we had come to the conclusion that it would be for the benefit of the profession generally, that, in addition to the existing medical corporations, a third should be established for the class of general practitioners."The consideration of the same facts, and the same process of reasoning, that led us to this conclusion, seem to have impressed the minds of the great body of general practitioners in the same manner; and the
Mesenchymal stem cells regulated DX5 – liver natural killer cells in rescuing acute-on-chronic liver failure murine
Authors: Jing Xiong, Bingliang Lin, Zhiliang Gao, Shi Qiu Xiong, Weizhen Weng, Dengna Lin, Jun-feng Chen, Hui Juan Cao, Shao Quan Zhang, Jing Zhang, Juan Gao
Journal: Journal of Hepatology (2020)
Prospectively Randomized Evaluation of Stentless Versus Conventional Biological Aortic Valves
Authors: Thomas Walther, Volkmar Falk, Georg Langebartels, Martin Krüger, Uta Bernhardt, Anno Diegeler, Jan Gummert, Rüdiger Autschbach, Friedrich W. Mohr
Journal: Circulation (1999)

Background —The aim of this prospectively randomized study was to evaluate left ventricular hypertrophy and its regression after stentless versus conventional biological aortic valve replacement. Methods and Results —From March 1996 through April 1998, 180 patients were prospectively selected; 106 patients received a stentless aortic valve (SAV), and 74 received a conventional stented bioprosthesis (CSB). Of these patients, 95% and 96%, respectively, had aortic stenosis. Their mean age was 72.3 and 74.8 years, and there were no significant differences in left ventricular function, preoperative pressure gradients, and NYHA functional status. Aortic annulus diameter indexes were comparable at 13.46 (SAV) versus 13.55 (CSB) mm ( P =NS). Larger SAVs were implanted because of the oversizing technique. In-hospital mortality (n=3 and 1 for SAV and CSB) was not valve related. At follow-up, all patients were in NYHA class 1 or 2. Baseline end-diastolic left ventricular posterior wall thickness was 15.6 (SAV) and 14.8(CSB) mm ( P =NS) and decreased to 11.8 (SAV) and 13.2 (CSB) mm ( P &lt;0.05) at 6 months. Left ventricular mass index was 213 and 202 g/m 2 at baseline ( P =NS), whereas after 6 months, it was 141 (SAV) and 170 (CSB) g/m 2 ( P &lt;0.05). Conclusions —Regression of left ventricular hypertrophy occurs in all patients after aortic valve replacement but is significantly enhanced after SAV implantation. This possibly is due to improved transvalvular hemodynamics.
Abstract O.64: Characteristics and Fate of Systemic Artery Aneurysm caused by Kawasaki disease
Authors: Shinsuke Hoshino, Etsuko Tsuda, Osamu Yamada
Journal: Circulation (2015)

Background: The long-term outcome of Systemic artery aneurysms (SAA) caused by Kawasaki disease (KD) remains unknown. SAA refers to aneurysms developing anywhere in the arterial system other than the coronary circulation. SAA included peripheral artery aneurysm (PAN) and aortic artery aneurysm. Methods: We investigated the characteristics and the fate of SAA in 20 patients (14 males and 6 females) from their medical records and angiograms. The onset age of KD ranged from 1 to 20 months with a median of 6 months. The interval from the onset of KD to the latest angiogram ranged from 16 months to 24 years (median 18 years). The residual rate of PAN and the incidence of stenotic lesions were analyzed by the Kaplan-Meier method in 11 pts, who had undergone initial angiograms within 4 months. Results: The mean duration of fever was 24±12 days. All 20 patients had at least a symmetric pair of aneurysms in bilateral peripheral arteries and 16 pts (80%) had multiple PAN. The number of respective SAA was as follows, brachial artery 32, common iliac artery 20, internal iliac artery 21, abdominal aortic aneurysm 7, and others 30. The residual rates of PAN at 10 and 20 years after the onset of KD were 66% and 51%, respectively (n=42). The incidence of stenotic lesions at 10 and 20 years after the onset of KD was 6 % and 25 %, respectively. The diameter of PAN in the acute phase leading to stenotic lesions in the late period was more than 10.0mm. Conclusions: PAN occurred symmetrically and were multiple in younger infants and those with severe acute vasculitis. The fate of PAN resembles that of coronary artery aneurysms, and depends on its acute phase diameter. The larger PAN can lead to stenotic lesions in the late period.
Radical radiotherapy for stage I/II non-small cell lung cancer in patients not sufficiently fit for or declining surgery (medically inoperable): a systematic review
Authors: N P Rowell, C J Williams
Journal: Thorax (2001)

OBJECTIVES To determine the effectiveness of radical radiotherapy in medically inoperable stage I/II non-small cell lung cancer (NSCLC) and the extent of treatment related morbidity. METHODS Randomised trials were sought by electronically searching the Cochrane Clinical Trials Register, and both randomised and non-randomised trials were sought by searching Medline and Excerpta Medica (Embase). Further studies were identified from references cited in those papers already identified by electronic searching. The studies included were those of patients of any age with stage I/II NSCLC receiving radiotherapy at a dose of &gt;40 Gy in 20 fractions over 4 weeks or its radiobiological equivalent. RESULTS Two randomised and 35 non-randomised studies were identified. One randomised and nine non-randomised studies did not meet the selection criteria, leaving one randomised and 26 non-randomised studies for analysis. In the randomised trial 2 year survival was higher following continuous hyperfractionated accelerated radiotherapy (CHART; 37%) than following 60 Gy in 30 fractions over 6 weeks (24%). An estimated 2003 patients were included in the 26 non-randomised studies; overall survival was 22–72% at 2 years, 17–55% at 3 years, and 0–42% at 5 years. Following treatment, 11–43% of patients died from causes other than cancer. Cancer specific survival was 54–93% at 2 years, 22–56% at 3 years, and 13–39% at 5 years. Complete response rates were 33–61% and local failure rates were 6–70%. Distant metastases developed in approximately 25% of patients. Better response rates and survival were seen in those with smaller tumours and in those receiving higher doses although the reasons for prescribing higher doses were not clearly stated. The outcome was worse in those with prior weight loss or poor performance status. Assessment of treatment related morbidity and effects on quality of life and symptom control were inconclusive because of the lack of prospective evaluation and paucity of data. CONCLUSIONS No randomised trials compared a policy of immediate radical radiotherapy with palliative radiotherapy given when patients develop symptoms. In the absence of such trials, radical radiotherapy appears to result in a better survival than might be expected had treatment not been given. A substantial, though variable, proportion of patients died during follow up from causes other than cancer. The optimal radiation dose and treatment technique (particularly with respect to mediastinal irradiation) remain uncertain.
"THAT ORANGE COLORED SLIP" AGAIN
Journal: JAMA (1924)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Elementary Physiology for Students.
Journal: JAMA (1893)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
The Medical Outcomes Study
Authors: Alvin R. Tarlov
Journal: JAMA (1989)

The Medical Outcomes Study was designed to (1) determine whether variations in patient outcomes are explained by differences in system of care, clinician specialty, and clinicians' technical and interpersonal styles and (2) develop more practical tools for the routine monitoring of patient outcomes in medical practice. Outcomes included clinical end points; physical, social, and role functioning in everyday living; patients' perceptions of their general health and well-being; and satisfaction with treatment. Populations of clinicians (n = 523) were randomly sampled from different health care settings in Boston, Mass; Chicago, Ill; and Los Angeles, Calif. In the cross-sectional study, adult patients (n = 22 462) evaluated their health status and treatment. A sample of these patients (n = 2349) with diabetes, hypertension, coronary heart disease, and/or depression were selected for the longitudinal study. Their hospitalizations and other treatments were monitored and they periodically reported outcomes of care. At the beginning and end of the longitudinal study, Medical Outcomes Study staff performed physical examinations and laboratory tests. Results will be reported serially, primarily inThe Journal. (<i>JAMA</i>. 1989;262:925-930)
Rare hyper-, hypothyroid states require unconventional therapies
Authors: T. Ziporyn
Journal: JAMA (1985)

Once upon a time there were hyperthyroidism and hypothyroidism. Therapy for the first aimed at diminishing excess hormone production, while therapy for the second aimed at replacing it. But now research from a variety of laboratories suggests that in certain conditions these therapeutic approaches, however logical on the surface, may be unnecessary and even dangerous. Some of these relatively rare conditions were discussed at the Seventh International Congress of Endocrinology in Quebec City and at the annual meeting of the American Thyroid Association in New York City. The recurrent message was: Hyperthyroidism is not always hyperthyroidism. And the same holds true for hypothyroidism. For example, at the endocrinology meeting, held last summer, Thomas F. Nikolai, MD, discussed a condition noticed at the Marshfield (Wis) Clinic and regarded as a clinically new form of hyperthyroidism not recognized before 1970. Called "silent thyroiditis" (or lymphocytic thyroiditis with spontaneously resolving hyperthyroidism), this disease
Re: Telomerase Activity in Human Breast Tumors
Authors: E. HIYAMA, L. GOLLAHON, T. KATAOKA, K. KUROI, T. YOKOYAMA, A. F. GAZDAR, K. HIYAMA, M. A. PLATYSZEK, J. W. SHAY
Journal: JNCI Journal of the National Cancer Institute (1996)

similar significant prolongations in normal quality-of-life parameters, such as physical symptoms, anxiety, and depression (all values P<.04, repeated-measures analysis of covariance) (5).The above data, in conjunction with the meta-analysis presented by the authors, help us to define more clearly the potential survival advantages with the use of HAI in the treatment of patients with nonresectable liver metastases from colorectal cancer.